%20and%20Batch%20Production%20Records%20(BPR).png)
Empagliflozin & Sitagliptin - Landmark Trials Revisited in 2026
In this episode of Diabetes Wellness Forum, titled, "Empagliflozin & Sitagliptin - Landmark Trials Revisited in 2026", Dr Nandita Mohan from Medical Dialogues is in conversation with Dr Dheeraj Kapoor, Chief of Endocrinology, Artemis Hospital, Gurgaon and Dr Swayamsidha Mangaraj, Professor, Department of Endocrinology, IMS and SUM Hospital, Bhubaneswar, to discuss critical aspects of diabetes care in 2026.
Empagliflozin and Sitagliptin are well-established and widely used agents in the long-term management of type 2 diabetes. As diabetes care continues to evolve from major innovations to micro-innovations, new fixed-dose combinations such as Empagliflozin–Sitagliptin FDC and Empagliflozin–Sitagliptin–Metformin FDC have emerged, offering greater convenience and therapeutic synergy. Revisiting the evidence supporting these agents is essential to optimize their use in routine practice. Understanding their complementary mechanisms and clinical data will help clinicians apply them more effectively in 2025 for improved patient outcomes.
During this episode, the experts address three key clinical questions:
1. What are the key benefits of empagliflozin based on the landmark clinical trial evidence over the last decade?
2. What are the key benefits of Sitagliptin based on the landmark clinical trial evidence over the last one and a half decades?
3. In which patient profiles would you consider Empagliflozin Sitagliptin Metformin FDC?
Apa Reaksi Anda?
Suka
0
Kurang Suka
0
Setuju
0
Tidak Setuju
0
Bagus
0
Berguna
0
Hebat
0
